Mirabaud & Cie SA MRNA — MODERNA INC

Ownership history in Mirabaud & Cie SA  ·  8 quarters on record

AI Ownership Summary

Mirabaud & Cie SA reported MODERNA INC (MRNA) in 8 quarterly 13F filings from 2024 Q2 through 2026 Q1. Peak portfolio weight reached 2.21% in 2024 Q2. The latest visible filing shows MRNA at 0.38% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this MRNA ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Mirabaud & Cie SA's position in MODERNA INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

MRNA was reported at 0.38% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
2.21% in 2024 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q2 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

MRNA stock page Mirabaud & Cie SA fund profile Mirabaud & Cie SA full holdings
How Mirabaud & Cie SA held MRNA — position size vs. price
% of Fund (quarterly)    MRNA price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 8 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 REDUCED — — — 18,366 -32,060 -63.6% 0.38% $933K 2026-05-05 $46.71
2025 Q4 REDUCED — — — 50,426 -120 -0.2% 0.48% $1.5M 2026-01-16 $41.83
2025 Q3 REDUCED 15.8% +20.6% ❌ 50,546 -9,486 -15.8% 0.41% $1.3M 2025-10-16 $27.14
2025 Q2 REDUCED — — — 60,032 -1,510 -2.5% 0.53% $1.7M 2025-07-08 $32.54
2025 Q1 ADDED — — — 61,542 +3,520 +6.1% 0.60% $1.7M 2025-05-09 $24.25
2024 Q4 ADDED — — — 58,022 +1,694 +3.0% 0.77% $2.4M 2025-01-17 $34.06
2024 Q3 REDUCED 15.5% -41.1% ✅ 56,328 -10,355 -15.5% 1.09% $3.8M 2024-11-01 $54.63
2024 Q2 INITIATED — — — 66,683 — — 2.21% $6.6M 2024-09-30 $66.83

🏢 Other funds also holding MRNA

As of 2026 Q1 — sorted by position size

Green Alpha Advisors, LLC 3Y 1.72% CHAPIN DAVIS, INC. 3Y 1.42% Legal Advantage Investments, Inc. 3Y 1.26% BANQUE PICTET & CIE SA 3Y 7Y 0.98% Douglas Lane & Associates, LLC 3Y 7Y 0.96% PATTON FUND MANAGEMENT, INC. 3Y 0.76% Montaka Global Pty Ltd 0.61% Leonteq Securities AG 0.57% Friedenthal Financial 3Y 7Y 0.55% Blue Sky Capital Consultants Group, Inc. 0.5%

FAQ About Mirabaud & Cie SA and MRNA

These are the practical questions this page is built to answer before you even open the full history table.

How long has Mirabaud & Cie SA reported owning MRNA?

Mirabaud & Cie SA reported MRNA across 8 quarterly 13F filings, from 2024 Q2 through 2026 Q1.

What was the largest reported MRNA position in Mirabaud & Cie SA's portfolio?

The largest reported portfolio weight for MRNA was 2.21% in 2024 Q2.

What is the latest reported MRNA position on this page?

The most recent filing on this page is 2026 Q1, when Mirabaud & Cie SA reported 18,366 shares, equal to 0.38% of portfolio, with an estimated market value of $933K.

What does the chart on this MRNA ownership page compare?

The chart compares Mirabaud & Cie SA's quarterly MRNA portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Mirabaud & Cie SA time their MRNA position?

Based on 13F filing dates vs. subsequent MRNA price moves, Mirabaud & Cie SA correctly timed 3 out of 7 reported position changes (43%). The annualised alpha on MRNA relative to SPY over the holding period was -31.7%.

← Back to Mirabaud & Cie SA Holdings